Implantable microencapsulated dopamine (DA): a new approach for slow-release DA delivery into brain tissue.
Biodegradable controlled-release systems constitute an exciting new technology for drug delivery to the central nervous system (CNS). The present study describes functional and histochemical observations, indicating that implantation of DA microcapsules into striatal tissue assures a prolonged release of the transmitter in situ. This technology has considerable potential for basic and possibly also clinical research.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D002214:Capsules; D003342:Corpus Striatum / Q000187:drug effects* / Q000502:physiology; D003692:Delayed-Action Preparations; D004298:Dopamine / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000502:physiology; D004343:Drug Implants; D006892:Hydroxydopamines; D008297:Male; D008474:Medial Forebrain Bundle / Q000187:drug effects; D016627:Oxidopamine; D051381:Rats; D011919:Rats, Inbred Strains; D013239:Stereotyped Behavior / Q000187:drug effects
D002214:Capsules; D003692:Delayed-Action Preparations; D004343:Drug Implants; D006892:Hydroxydopamines; D016627:Oxidopamine; D001058:Apomorphine; D004298:Dopamine